EconomySingapore biomedical startups expand into China to speed cancer and diabetes treatments

Singapore biomedical startups are entering China to speed development of treatments for cancer and diabetes. A*STAR spin-offs Lion TCR and BetaLife are using the country’s large patient pool, hospital networks and manufacturing capacity to advance trials and research, while navigating changing regulations. Enterprise Singapore is helping them understand approval routes and form partnerships.